Haselkorn Tmirah, Szefler Stanley J, Chipps Bradley E, Bleecker Eugene R, Harkins Michelle S, Paknis Brandee, Kianifard Farid, Ortiz Benjamin, Zeiger Robert S
EpiMetrix, Inc, Los Altos, Calif.
The Breathing Institute, Children's Hospital Colorado, Aurora, Colo; Department of Pediatrics, Section of Pediatric Pulmonary and Sleep Medicine, University of Colorado School of Medicine, Aurora, Colo.
J Allergy Clin Immunol Pract. 2020 Jul-Aug;8(7):2243-2253. doi: 10.1016/j.jaip.2020.02.040. Epub 2020 Mar 12.
Severe/difficult-to-treat disease occurs in 5% to 10% of patients with asthma, but accounts for more than 50% of related economic costs. Understanding factors associated with persistent very poorly controlled (VPC) asthma may improve outcomes.
To characterize persistent VPC asthma after more than 10 years of standard of care.
The Epidemiology and Natural history of asthma: Outcomes and treatment Regimens (TENOR) II (N = 341) was a multicenter, observational study of patients with severe/difficult-to-treat asthma with a single, cross-sectional visit more than 10 years after TENOR I. Persistent VPC asthma was defined as VPC asthma at TENOR I and TENOR II enrollment; without VPC asthma was defined as well- or not well-controlled asthma at either or both visits. Multivariable logistic regression assessed long-term predictors of persistent VPC asthma using TENOR I baseline variables.
Of 327 patients, nearly half (48.0%, n = 157) had persistent VPC asthma. Comorbidities and asthma triggers were more frequent in patients with persistent VPC asthma than in patients without VPC asthma. Total geometric mean IgE was higher in patients with persistent VPC asthma (89.3 IU/mL vs 55.7 IU/mL); there was no difference in eosinophil levels. Lung function was lower in patients with persistent VPC asthma (mean % predicted pre- and postbronchodilator FEV, 63.0% vs 82.8% and 69.6% vs 87.2%, respectively). Exacerbations in the previous year were more likely in patients with persistent VPC asthma (29.7% vs 9.0%, respectively). Predictors of persistent VPC asthma were black versus white race/ethnicity, allergic trigger count (4 vs 0), systemic corticosteroid use, and postbronchodilator FEV (per 10% decrease).
The burden of persistent VPC asthma is high in severe/difficult-to-treat disease; management of modifiable risk factors, maximization of lung function, and trigger avoidance may improve outcomes.
5%至10%的哮喘患者患有严重/难治性疾病,但其相关经济成本却占比超过50%。了解与持续性控制极差(VPC)哮喘相关的因素可能会改善治疗效果。
对超过10年遵循标准治疗的持续性VPC哮喘进行特征描述。
哮喘的流行病学和自然史:结局与治疗方案(TENOR)II(N = 341)是一项多中心观察性研究,研究对象为患有严重/难治性哮喘的患者,在TENOR I之后超过10年进行单次横断面访视。持续性VPC哮喘定义为在TENOR I和TENOR II入组时均为VPC哮喘;无VPC哮喘定义为在任意一次或两次访视时为控制良好或控制不佳的哮喘。多变量逻辑回归使用TENOR I基线变量评估持续性VPC哮喘的长期预测因素。
在327例患者中,近一半(48.0%,n = 157)患有持续性VPC哮喘。持续性VPC哮喘患者的合并症和哮喘触发因素比无VPC哮喘患者更常见。持续性VPC哮喘患者的总几何平均免疫球蛋白E(IgE)更高(89.3 IU/mL对55.7 IU/mL);嗜酸性粒细胞水平无差异。持续性VPC哮喘患者的肺功能更低(支气管扩张剂前后预计FEV平均值分别为63.0%对82.8%和69.6%对87.2%)。持续性VPC哮喘患者前一年的急性加重更有可能发生(分别为29.7%对9.0%)。持续性VPC哮喘的预测因素为黑人与白人种族/族裔、过敏触发因素数量(4对0)、全身使用糖皮质激素以及支气管扩张剂后FEV(每降低10%)。
在严重/难治性疾病中,持续性VPC哮喘的负担很高;管理可改变的风险因素、最大化肺功能以及避免触发因素可能会改善治疗效果。